Approvals/TGA/ODEFSEY emtricitabine (200 mg), rilpivirine (25 mg), tenofovir alafenamide (25 mg) fixed-dose combination tablet

Approved

STANDARD

ODEFSEY emtricitabine (200 mg), rilpivirine (25 mg), tenofovir alafenamide (25 mg) fixed-dose combination tablet

Gilead Sciences Pty Ltd🇦🇺 Therapeutic Goods Administration

Approval Id: cf01b510528a39c7
Product Name: ODEFSEY emtricitabine (200 mg), rilpivirine (25 mg), tenofovir alafenamide (25 mg) fixed-dose combination tablet
Artg Id: 260634
Artg Name: ODEFSEY emtricitabine (200 mg), rilpivirine (25 mg), tenofovir alafenamide (25 mg) fixed-dose combination tablet
Sponsor: Gilead Sciences Pty Ltd
Company Detail Path: /organization/gilead-sciences-pty-limited
Artg Date: 2016-08-30
Registration Type: Medicine
Therapeutic Good Type: Medicine
Licence Status: A
Licence Category: RE
Consumer Medicine Info: https://medical-cdn.nocode.com/drug_tga/1f324d3b07c3376375279ebfb98446b3.pdf
Product Information: https://medical-cdn.nocode.com/drug_tga/4d3dda2a3a179e3d7022b679b92622df.pdf

Approved

Agency

TGA

Country

🇦🇺

Approval Date

May 29, 2025

Approval ID

cf01b510528a39c7

Type

Standard